Teva Pharmaceutical Industries Limited TEVA
43.47 USD +0.23 (+0.53%)
Nov 12, 2026, 10:06 AM EST
43.19 Day range 43.75
24.21 52-week range 43.46
- YTD
- +39.28%
- 1 year
- +68.29%
News
benzinga.com Piper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $56 Piper Sandler analyst David Amsellem maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $44 to $56.
marketbeat.com Teva Pharmaceutical Industries Targets Up to $7 Billion in Innovative Drug Revenue by 2030 Teva Pharmaceutical Industries NYSE: TEVA outlined plans to grow its innovative medicines business and advance a pipeline spanning neuroscience, immunology and cancer treatments at its first R&D Day.
benzinga.com Teva Outlines Aggressive R&D Strategy with $7 Billion in Innovative Medicine Revenue by 2030 Teva Pharmaceutical outlines a $7 billion innovative medicine revenue goal by 2030 at its first R&D Day, detailing pipeline and financial growth.
benzinga.com Teva Pharma Unveils Long-Term Growth Strategy, Targets $6B-$7B In Innovative Medicines Revenue By 2030 The Company has more than doubled revenue from innovative medicines since launching Pivot to Growth in 2023, demonstrating sustained execution and the growing strength of its high-velocity biopharma…
globenewswire.com Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030 Teva hosts its first R&D Day, sharing pipeline updates and a target of $6–7 billion in innovative medicines revenue by 2030 as a high-velocity biopharma.
fool.com Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now? Teva improved margins significantly. The pharmaceutical company has paid down net debt.
defenseworld.net What Teva Pharmaceutical Industries (TEVA) Said on Its Q3 Earnings Call Teva Pharmaceutical Industries (NYSE: TEVA) reported third-quarter 2026 revenue of approximately $4.4 billion, down 2% from a year earlier, as growth in its innovative medicines portfolio was offset…
benzinga.com Leerink Partners Maintains Outperform on Teva Pharmaceutical Indus, Raises Price Target to $52 Leerink Partners analyst Daniel Clark maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform and raises the price target from $45 to $52.
benzinga.com TD Cowen Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $57 TD Cowen analyst Joseph Thome maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $55 to $57.
benzinga.com MindWalk Holdings Inks Agreement With Teva Pharmaceuticals Australia To Deploy ReefIQ MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today announced a multi-year agreement with Teva Pharmaceuticals Australia Pty Ltd ("Teva Australia") to deploy ReefIQ™,
benzinga.com HC Wainwright & Co. Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $54 HC Wainwright & Co. analyst Douglas Tsao maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $52 to $54.
benzinga.com Teva CEO Sees Strong Austedo Demand Cushioning Medicare Pricing Blow in 2027 Teva stock jumps after beating Q3 earnings and boosting its 2026 outlook, powered by 33% branded drug growth.
benzinga.com Teva Pharmaceutical Indus Q3 2026 Earnings Call Transcript Teva Pharmaceutical Indus (NYSE:TEVA) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Teva Pharmaceutical Indus Raises FY2026 Adj EPS Guidance from $1.91-$2.11 to $1.92-$2.11 vs $1.98 Est; Raises FY2026 Sales Guidance from $16.500B-$16.850B to $16.700B-$17.000B vs $16.651B Est Teva Pharmaceutical Indus (NYSE:TEVA) raises FY2026 Adj EPS guidance from $1.91-$2.11 to $1.92-$2.11 vs $1.98 analyst estimate. Raises FY2026 sales outlook from $16.500 billion-$16.850 billion to…- benzinga.com Teva Pharmaceutical Indus Q3 Adj. EPS $0.86 Beats $0.73 Estimate, Sales $4.395B Beat $4.291B Estimate Teva Pharmaceutical Indus (NYSE:TEVA) reported quarterly earnings of $0.86 per share which beat the analyst consensus estimate of $0.73 by 17.81 percent. This is a 10.26 percent increase over…
benzinga.com Teva Expands Samsung Bioepis Collaboration With ETICOVO, Infliximab-Abda Deal; Upfront Payment Over 3 Years, Launch And Sales Milestones Possible, Profits Shared Teva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO® upon close and infliximab-abda in Q3 2027Collaboration combines Samsung Bioepis’ biosimilar expertise with Teva’s…
benzinga.com AMD, Shopify On Deck Tuesday As AI Spending, Merchant Growth Face Test Advanced Micro Devices headlines Tuesday’s reports, with investors looking for evidence that AI demand can withstand a sharp pullback in the stock. Shopify, Pfizer, Eaton, Marathon Petroleum and…
benzinga.com Why Is Teva Stock Trading Lower on Monday? Teva halts its Phase 2 TOPAS-MSA study after an interim futility analysis showed low odds of meeting the primary efficacy endpoint.
benzinga.com This GameStop Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Analysts initiated bullish coverage on Janus Living, GameStop, SharkNinja, Teva and H2O America, with targets of $33, $33, $245, $52 and $67.- benzinga.com HC Wainwright & Co. Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $52 HC Wainwright & Co. analyst Douglas Tsao initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy rating and announces Price Target of $52.
benzinga.com Teva Pharmaceuticals International GmbH Acquires BioXcel Therapeutics' Assets For $57.5M Upfront Payment Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that it has completed the acquisition of assets from BioXcel…- benzinga.com Teva Pharma And Sanofi Report Duvakitug Maintained Efficacy Through 44 Weeks In Ulcerative Colitis And Crohn's Disease In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44In CD, duvakitug maintained high rates of endoscopic response, clinical response,…
- benzinga.com Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $47 Barclays analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $42 to $47.
benzinga.com FDA Approves Teva's New Once-Monthly Schizophrenia Injection FDA approves Teva's Weltruza, a once-monthly injectable for adults with schizophrenia, eliminating the need for daily oral medication.- benzinga.com Teva Pharmaceuticals Receives FDA Approval Of WELTRUZA For Extended-Release Injectable Suspension For The Treatment Of Schizophrenia In Adults WELTRUZA clinical trial results demonstrated improvement in symptoms (PANSS), significant reduction in illness severity (CGI-S), as well as improvement in personal and social functioning (PSP).1 In…
- benzinga.com Teva Pharma Presents New Ecopipam Data Highlighting Potential Benefits For Pediatric Tourette Syndrome Patients At MDS 2026 Based on a post hoc analysis, a majority of participants (~70%) experienced clinically meaningful tic reduction within 8 weeks of starting ecopipamAn interim 18-month analysis of an ongoing…
- benzinga.com Teva Pharma Says Journal Of Child Neurology Publishes Comprehensive Review Examining Dopamine Pathways In Tourette Syndrome And Therapeutic Potential Of Ecopipam For Treatment Of Pediatric Patients With Tourette Syndrome The published review examines dopamine’s role in tic generation and how approved and investigational drugs may affect dopamine to reduce tics as well as synthesizes clinical trial evidence that…
benzinga.com This Toll Brothers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Analysts initiated bullish coverage on Vita Coco, Toll Brothers, Civeo, Teva and Kura Oncology, with price targets of $70, $159, $42, $55 and $30.- benzinga.com TD Cowen Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $55 TD Cowen initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy rating and announces Price Target of $55.
- benzinga.com Teva Pharmaceutical Industries Receives FDA Approval For DEGEVMA To Treat Bone Complications In Patients With Advanced Cancer Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved DEGEVMA™ (denosumab-adet) as a biosimilar to Xgeva®…
- benzinga.com Oppenheimer Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $50 Oppenheimer analyst Les Sulewski initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform rating and announces Price Target of $50.
- benzinga.com Teva Pharmaceuticals Presents Data Showing Healthcare Providers Prioritize Drowsiness Risk, Long-Term Response And Drug Interactions When Treating Older TD Patients New data revealed that healthcare providers prioritize drowsiness risk, duration of available data demonstrating long-term response and drug-drug interaction profile when selecting a treatment for…
- benzinga.com Teva Pharmaceuticals Presents Data Showing UZEDY Improves Treatment Continuity, Reduces Hospitalizations And Cuts Healthcare Costs In Schizophrenia And Bipolar I Disorder New findings show favorable treatment continuity for UZEDY compared to other long-acting injectables in schizophrenia, as well as oral antipsychotics in bipolar I disorder (BD-I)The new real-world…
- benzinga.com Teva Presents New SOLARIS Data Showing TEV-'749 Maintained Schizophrenia Stabilization And Supported Remission In Long-Term Use In a post hoc analysis of the open-label safety stage of the Phase 3 SOLARIS trial, more than half of participants receiving TEV-'749 achieved stabilization, few relapsed and more than one-fifth of…
benzinga.com Roche Receives EMA CHMP Recommendation Of Approval Ocrevus For Pediatric Patients With Relapsing Forms Of Multiple Sclerosis The U.S. FDA approved Ocrevus for paediatric RMS patients in May 2026. A final decision from the European Commission is expected in the near future."Children and teens living with multiple sclerosis…
benzinga.com Teva's Shares Now Trade Directly on the NYSE — Here's What Else Changed Teva Pharmaceutical Industries had a busy week that included a major debt refinancing, a NYSE trading shift and analyst activity.- benzinga.com Teva Priced Approximately $4.9B (Equivalent) of Senior Notes Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today that it successfully priced its offering of approximately $4.9 billion (equivalent) of senior notes (the "Notes").…
- benzinga.com Leerink Partners Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $45 Leerink Partners analyst Daniel Clark initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform rating and announces Price Target of $45.
- benzinga.com UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $48 UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $42 to $48.
benzinga.com Teva Reports Significant Prevention Of Gluten-Induced Damage in New Study Teva reports positive Phase 2a results for TEV '408, successfully preventing gluten-induced intestinal damage in adult celiac patients.- benzinga.com Teva Stock Rises After TEV '408 Meets Primary Endpoint in Celiac Disease Study Teva Pharma is trading higher after announcing positive topline results from a Phase 2a study of TEV '408, which met its primary endpoint.
- benzinga.com Teva Says Topline Results From Ongoing Phase 2a Study Of TEV ‘408 For Celiac Disease Met Its Primary Endpoint, Demonstrating Statistically Significant And Clinically Meaningful Prevention Of Gluten-induced Intestinal Damage Versus Placebo At Week 8 Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced positive topline results from an ongoing Phase 2a study of TEV ‘408, an investigational anti-interleukin-15 monoclonal…
benzinga.com Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President Trump secures drug pricing deals with nine pharma companies as Kennedy reveals intense pressure from the President to deliver.- benzinga.com Teva And Trump Administration Commit To Lowering Select Medicaid Drug Costs Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a shared commitment with the Trump Administration to lower the cost of select…
- benzinga.com Trump Administration Reaches New Drug Pricing Agreement With Nine Pharma Firms https://www.whitehouse.gov/fact-sheets/2026/08/fact-sheet-president-donald-j-trump-announces-deal-with-nine-additional-pharmaceutical-manufacturers-to-lower-drug-prices-for-americans/
benzinga.com BioXcel Stock Plunges: Chapter 11 Filing Triggers Teva Stalking Horse Bid BioXcel Chapter 11 sends BTAI shares sharply lower as Teva becomes the stalking horse bidder for IGALMI and BXCL501 assets.
benzinga.com Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug Aurinia Pharmaceuticals shares rise after settling patent litigation with Teva, which can launch generic voclosporin no earlier than December 2036.- benzinga.com Aurinia Settles Teva Patent Litigation, Protecting Voclosporin Exclusivity In U.S. Until December 2036 And Affirming Validity Of Key Patents Through 2037 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, "Aurinia") have entered into a settlement agreement with Teva…
- benzinga.com Teva Pharmaceuticals' New Drug Application For Ecopipam Gets FDA Acceptance To Treat Pediatric Patients With Tourette Syndrome Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application…
- benzinga.com Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $42 Barclays analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $40 to $42.